Gonadorelin vs hCG

community guides:

related topics:

Community Q&A

What is the difference between gonadorelin and hCG for TRT?

Community accounts from men on TRT address this comparison directly and with clinical specificity. hCG (human chorionic gonadotropin) acts at the LH receptor on the testes and directly stimulates testosterone production and testicular function — it has been the standard TRT adjunct for fertility and testicular maintenance. Gonadorelin is a GnRH analogue that acts upstream, stimulating the pituitary to release LH and FSH naturally. Accounts describe the practical difference: hCG bypasses the pituitary and acts directly on the testes; gonadorelin preserves the entire HPT axis. Men who switched from hCG to gonadorelin in accounts describe similar testicular maintenance but a more natural hormonal pattern, with LH and FSH restored alongside testicular response.

Why are people switching from hCG to gonadorelin?

The hCG-to-gonadorelin transition is one of the more discussed shifts in the TRT community accounts in the archive. The primary driver: hCG compounding was restricted in the US in 2020, limiting compounding pharmacy access and forcing many men on prescribed TRT protocols to find alternatives. Gonadorelin emerged as the primary replacement because it achieves similar HPT axis preservation goals through a different mechanism. Accounts from men who switched describe comparable testicular maintenance outcomes, though some describe needing more frequent dosing with gonadorelin compared to hCG's typical twice-weekly protocol. A secondary reason described in accounts: some men preferred gonadorelin's pituitary-level mechanism as more physiologically upstream, though accounts are split on whether this produces a meaningful clinical difference.

Does gonadorelin work as well as hCG for fertility on TRT?

Community accounts addressing fertility preservation on TRT describe gonadorelin as functional but with more variability than hCG in community reporting. Accounts from men who successfully maintained fertility markers (sperm count, testicular volume) while on TRT describe gonadorelin working when dosed consistently and frequently — most protocols described in accounts run it 2–3 times weekly. The accounts that describe gonadorelin failing for fertility typically involve infrequent dosing or delayed introduction after extended TRT suppression. The underlying mechanism explains the pattern: gonadorelin requires a responsive pituitary, whereas hCG acts directly on the testes — for men whose pituitary has been suppressed for an extended period, accounts suggest gonadorelin may not restore the feedback loop as readily. The consistent recommendation across accounts: introduce gonadorelin early rather than after years of unsupplemented TRT.

What dose and protocol do community accounts describe for gonadorelin on TRT?

Gonadorelin protocols on TRT are described with more variability in community accounts than hCG protocols were — partly because gonadorelin is newer as a TRT adjunct and partly because the dosing literature is less established. The most common dosing pattern in accounts: 100–250mcg subcutaneous, 2–3 times per week, co-administered on non-testosterone injection days where possible to avoid hormonal stacking at a single time point. Accounts from clinic patients describe provider-prescribed gonadorelin in the 100mcg range; grey-market accounts describe experimenting at higher doses. The key practical point: gonadorelin's short half-life (minutes) means pituitary stimulation is brief — accounts describe administering it multiple times per week as necessary for sustained HPG axis stimulation, in contrast to hCG's longer half-life that allowed twice-weekly dosing. Accounts that switched from hCG to gonadorelin typically increase administration frequency from twice to three times weekly to compensate for the shorter duration of action.